Multicenter phase 2 study of ciltacabtagene autoleucel for relapsed or refractory multiple myeloma in Chinese patients

Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy. The multicenter phase 2 CARTIFAN-1 trial in China found that a single cilta-cel infusion resulted in early, deep, and durable responses among heavily pretreated patients with relapsed or refractory multiple myeloma. Grade 5 treatment-related adverse events occurred in 16.6% of patients. The authors conclude that cilta-cel for RRMM had a favorable risk-benefit profile.